Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries

INTRODUCTION: The aim of this work is to compare real-world outcomes of patients with rheumatoid arthritis (RA) receiving adalimumab (ADA) bio-originator (non-switchers) to those who had switched from ADA bio-originator to an ADA biosimilar (switchers) on the basis of the hypothesis that these outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Gonzalez, Yuri Sanchez, Clark, Ryan, Faccin, Freddy, Howell, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834672/
https://www.ncbi.nlm.nih.gov/pubmed/36631636
http://dx.doi.org/10.1007/s40744-022-00526-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834672/
https://www.ncbi.nlm.nih.gov/pubmed/36631636
http://dx.doi.org/10.1007/s40744-022-00526-w

Ejemplares similares